220) dynamic data for decision-making for both patients and clinicians. |
221) sitivity rates did not differ between SLE patients and controls. |
222) e feasible to address EOL outcomes for AA patients and families experiencing serious |
223) MTBC) isolates were obtained from 191 TB patients and genotyped into different phyl |
224) Our results show that sera from both patients and healthy controls had IgG and |
225) measured in banked serum samples from SLE patients and healthy controls in the Oklah |
226) ectin-2, Mincle, Mcl) from 42 haematology patients and investigated each patient's a |
227) tivation of HIFs has been demonstrated in patients and mouse models of NAFLD and NAS |
228) rs for improved AKI diagnosis in COVID-19 patients and new treatment options are req |
229) h altered network connectivity between AD patients and normal individuals involved i |
230) potential for PET imaging studies in ALS patients and possibly other brain disorder |
231) er transplantation in adult and pediatric patients and require retransplantation. |
232) tion hesitancy were identified among both patients and rheumatologists: 'social and |
233) clinical and economic burdens on affected patients and societies. |
234) d significant morbidity and mortality for patients and stressed healthcare systems w |
235) practice in communication with pediatric patients and their families. |
236) e management of neonatal single ventricle patients, and 90% also use the drug in sub |
237) r cells promote inflammation in asthmatic patients, and both Th2 and Th17 CD4 T cell |
238) Treatment effects vary across different patients, and estimation of this variabili |
239) l as it manifests very differently across patients, and even within families, with o |
240) ally regulated circulating miRNAs in TNBC patients, and integrated pathway regulatio |
241) simplify the imaging process of COVID-19 patients, and potentially reduce the strai |
242) he imaging dose, especially for pediatric patients, and to lessen the need for conto |
243) hare best practice in relation to WMI for patients/consumers and to develop and impl |
244) Patients were injected with 30 mL of 20 μ |
245) We found that patients were able to use reinforcement si |
246) synovial fluid samples from no-RA and RA patients were collected; the collagen-indu |
247) l time and chemotherapy responses between patients were compared with the TT genotyp |
248) sed different criteria to determine which patients were eligible for tapering, which |
249) Results: A total of 456 patients were eligible. |
250) 274 patients were included and 210 (76.6%) ret |
251) Eleven studies with a total of 7,015 patients were included in our analysis. |
252) ed 118 papers, of which 10 papers with 90 patients were included. |
|